Immune Thrombocytopenia: Expert Guidance to Integrate Emerging Therapies Into Clinical Practice

Immune Thrombocytopenia: Expert Guidance to Integrate Emerging Therapies Into Clinical Practice is organized by Clinical Care Options (CCO), LLC.,Released: September 15, 2022,Expiration: September 14, 2023,Goal:,The goal of this activity is to improve the knowledge, competence, and performance of learners in using new and emerging therapeutic options for patients with immune thrombocytopenia.,Learning Objectives:,Upon completion of this activity, participants should be able to:,• Identify newly diagnosed patients with ITP who would benefit from intensified therapy to improve remission rates,• Select optimal second or subsequent lines of therapy for patients with ITP who have had an insufficient response to corticosteroids, immunoglobulins, splenectomy, and/or a thrombopoietin receptor agonist,• Plan therapeutic strategies to manage thrombocytopenia in special populations of patients, including children, pregnant women, and those with COVID-19, with chronic liver disease, undergoing a planned medical procedure, or receiving chemotherapy,• Evaluate new clinical trial data and the clinical practice implications of novel targeted therapies in patients with immune thrombocytopenia,• Discuss ongoing clinical trials investigating novel targeted therapies and combination regimens for the treatment of immune thrombocytopenia,Additional details will be posted as soon as information is available.